Biocon Limited · NSE:BIOCON
Biocon — FY2022 Earnings Presentation
31 slides from Biocon's earnings presentation, Apr 28, 2022
Slide 1: Q4 and Full Year FY22 Investor Presentation
Q4 and Full Year FY22 Investor Presentation April 2022 B I O C O N L I M I T E D 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 3: Biocon is a global biopharmaceutical enterprise
Biocon is a global biopharmaceutical enterprise that is led by a purpose to develop innovative solutions that provide affordable access to high quality, essential and life saving medicines for patients, payers and health systems across the world. B I O C O N L I M I T E D 3
Slide 4: The Biocon Manifesto
The Biocon Manifesto accessibility affordability • Use our science, scale and • Focus on the kind of expertise to enhance access innovation that adds the to essential drugs for condition of affordability to As a committed stakeholder of patients on the lowest rung accessibility of the economic ladde
Slide 5: The Biocon Value Creation Journey
The Biocon Value Creation Journey 1978- 2000- 2005- 2010- 2016- 2019 & 1999 2004 2009 2015 2018 Beyond An Transforming Building the Base Strategic Global Commercialized Poised for Enzymes into a Business and Alliance with Mylan Biosimilars for Global Impact Company Biopharma Expertise in for Biosimi
Slide 6: Biocon Today: Strategically poised for a strong global play
Biocon Today: Strategically poised for a strong global play Rs 8,397 Cr | $1.1bn 13,500+ Revenue* Total Employees* 1,280+ 25+ Patents cGMP approvals from International regulatory agencies 120+ Ranked 5 Countries where Among Top 10 Global our products are Biotech Employers by available Science magazi
Slide 7: Sustainability at Biocon
Sustainability at Biocon Philosophy of ‘Unconditional Equity’ PATIENT EQUITY PEOPLE EQUITY SOCIAL EQUITY ENVIRONMENTAL EQUITY STAKEHOLDER EQUITY o 3.1M patients reached o Top 5 among global pharma & o Focus on Primary healthcare, o 53% electricity came from green o Independent Boards; Professional t
Slide 8: Business Segments
Business Segments B I O C O N L I M I T E D 8
Slide 9: Growth Verticals: Aligned With Shifting Paradigms
Growth Verticals: Aligned With Shifting Paradigms From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality and affordable healthcare products & services globally. Ensuring Expanding Pushing Partnering to access through access through scientific deliver
Slide 10: Generics: API – the building blocks
Generics : API – the building blocks API Business : Overview API : Growth Drivers across Strategic Priorities Among world’s largest manufacturers of immunosuppressant & • Expanding beyond • Expanding in statin APIs; leadership in Fermentation based APIs fermentation-based APIs select key (e.g. pepti
Slide 11: Generics: Forward integrating to Generic Formulations
Generics : Forward integrating to Generic Formulations Generic Formulations Business - Overview Growth Drivers across Strategic Priorities • Expanding portfolio through Adding capabilities Leveraging in-house API expertise to forward integrate and move up - Vertical integration & - injectable facili
Slide 12: Generics: Q4FY22 and full year FY22 Update
Generics: Q4FY22 and full year FY22 Update KEY Q4 HIGHLIGHTS Q4FY22 Q4FY21 Revenue Robust sequential and YoY growth in Q4 driven by API sales ramp ₹717Cr ₹570Cr +26% up, new launches in the US & normalization of operations Profit Before Tax (PBT) Posaconazole and Dorzolamide, launched in the US; 1st
Slide 13: Biosimilars: Overview
Biosimilars : Overview Leadership in biologics R&D, manufacturing and 8 2 3 25+ commercialization built over two decades Approved Research & Manufacturing sites cGMP approvals Products1 Development sites (2 Bengaluru, 1 Malaysia) (incl. FDA & EMA) Driven by high scientific acumen with analytical and
Slide 14: Biosimilar strategy resulted in several 'firsts'
Biosimilar strategy resulted in several ‘firsts’ Achieved many firsts in the space despite the nascent biosimilars regulatory pathway, setting new benchmarks for the industry 2004 2017 2018 2021 1st company to 1st company to 1st company to commercialize 1st company to receive receive approval receiv
Slide 15: Growing participation in global biosimilars market
Growing participation in global biosimilars market PA R T N E R BBL ROLE BBL ECONOMICS Biosimilars co-developed and co-commercialized with R&D and manufacturing led by BBL (2009) Set of next-gen biosimilars being co-developed (2018) Independently developing several biosimilar assets (ONGOING) Acquis
Slide 16: Acquisition of Viatris' biosimilars business
Acquisition of Viatris’ biosimilars business to add financial depth and global commercial capabilities… 1 Revenue EBITDA BBL to realize full revenue and profits Financial $1.1b | $250m from all its collaboration programs Viatris Biosimilars CY23 estimate1 2 Commercialization, Supply Chain and Operat
Slide 17: Biosimilar Value Chain
…transforming into a fully-integrated global biosimilars business POST ACQUISITION OF VIATRIS’ BIOSIMILARS CURRENT BUSINESS Emerging Markets Developed Markets Global Markets PRODUCT DEVELOPMENT ✓ ✓ ✓ ✓ ✓ ✓ Biosimilar Value Chain CLINICAL TRIALS R E G U L AT O R Y ✓ ✓ M AN U FAC T U R I N G ✓ ✓ ✓ S
Slide 18: Entering adjacencies in communicable disease: antibodies and vaccines
Entering adjacencies in communicable disease: infectious disease antibodies and vaccines Key Commercial Products (COVID-19) Recent Collaborations 50,000+ lives impacted Continued portfolio expansion 18 B I O C O N L I M I T E D 18
Slide 19: Asset-light entry into vaccines through SILS alliance
Asset-light entry into vaccines through SILS alliance BBL RIGHTS 1 Access to 100m doses of vaccines annually for 15 years 2 Commercialization rights of the SILS portfolio for global markets 3 BBL to have committed revenue stream and related margins from H2 FY23 Alliance to commercialize SILS COVID p
Slide 20: Comprehensive portfolio of biosimilars and vaccines
Comprehensive portfolio of 20 biosimilars and vaccines… Biosimilar Product Status Therapeutic Area Molecule US Dev. Markets: ex-US MoW 4 Commentary Pegfilgrastim1 Europe, CANZ - bBevacizumab: Approved in EU, Canada 1 Trastuzumab Europe, CANZ and Australia; US approval awaiting site Oncology Bevacizu
Slide 21: Set up to deliver sustainable growth trajectory
…set up to deliver sustainable growth trajectory BIOCON BIOLOGICS GROWTH DRIVERS Today < 2 years 2-4 years >4 years - Pegfilgrastim - Bevacizumab (US) - Aflibercept2 - Pertuzumab - Trastuzumab - Aspart (US) - Ustekinumab - Glargine 300 IU - Bevacizumab (EU) - Adalimumab (US) - Denosumab - Seven undi
Slide 22: Biosimilars: Q4FY22 and full year FY22
Biosimilars : Q4FY22 and full year FY22 Q4 FY22 Q4 FY21 FY22 FY21 Revenue ₹982Cr ₹664Cr +48% ₹3,464Cr ₹2,800Cr +24% Core EBITDA* ₹382Cr ₹215Cr +78% ₹1,320Cr ₹1,010Cr +30% % margin 39% 33% 39% 36% Profit Before Tax ₹144Cr ₹69Cr +109% ₹543Cr ₹365Cr +49% before Exceptional Items % margin 15% 10% 16% 13
Slide 23: Biocon Biologics offers differentiated value proposition
Biocon Biologics offers differentiated value proposition through its state-of-the-art platform 1 Fully integrated global biosimilars company (lab to market) 2 Strong commercial presence in global markets 3 Comprehensive portfolio of biosimilars and vaccines 4 Global scale biologics manufacturing cap
Slide 24: Novel Molecules: Pushing scientific boundaries
Novel Molecules: Pushing scientific boundaries to deliver impactful innovations Disease Area Asset Current Progress Insulin Tregopil- a first- • Phase I multiple ascending dose studies in Type 1 DM patients ongoing in Germany; in partnership with US-based Juvenile in-class oral, prandial Diabetes Re
Slide 25: Novels: Pipeline Progress made in Q4FY22
Novels: Pipeline Progress made in Q4FY22 KEY HIGHLIGHTS Pivotal Phase III clinical study of Itolizumab for aGVHD* initiated in March 2022 Bicara# initiated dose expansion cohorts evaluating BCA101 in patients with head and neck, anal canal & cutaneous squamous cell carcinoma *Acute Graft-Versus-Host
Slide 26: Research Services (Syngene): Overview
Research Services (Syngene) : Overview Offering integrated research, development & manufacturing services for small & large molecules, antibody-drug conjugates & oligonucleotides backed by best-in-class bioinformatic services World-class R&D and manufacturing infrastructure spread over 2 million squ
Slide 27: Research Services: Q4FY22 and full year FY22
Research Services: Q4FY22 and full year FY22 KEY Q4 HIGHLIGHTS Q4FY22 Q4FY21 Revenue ₹758Cr ₹659Cr +15% Performance across all divisions in Q4 Profit Before Tax (PBT) ₹179Cr ₹158Cr +14% Particularly strong quarter for Development Services on account of 24% of revenue 24% of revenue catching up on ea
Slide 28: Financial Highlights
Financial Highlights B I O C O N L I M I T E D 28
Slide 29: Financial Highlights: Q4FY22
Financial Highlights: Q4FY22 Q4FY22 Q4FY21 Biosimilars +48% | Generics +26% | Research Services +15% Revenue +21% ₹2,476Cr ₹2,048Cr Dilution Gain in Bicara of ₹30Cr vs ₹160Cr in Q4FY21 Core EBITDA* +37% ₹815Cr ₹594Cr Mark-to-market loss on investments of ₹6Cr % margin 33% 32% Forex Gain of ₹2Cr vs ₹
Slide 30: Financial Highlights: FY22
Financial Highlights: FY22 FY22 FY21 Biosimilars +24% | Research Services +19% | Generics -1% Revenue +14% ₹8,397Cr ₹7,398Cr Dilution Gain in Bicara of ₹30Cr vs ₹160Cr in FY21 Core EBITDA* +18% ₹2,669Cr ₹2,270Cr Mark-to-market loss on investments of ₹28Cr; Forex Gain of ₹58Cr vs loss of ₹9Cr % margi
Slide 31: Thank You
Thank You INVESTOR RELATIONS CONTACT: Aishwarya Sitharam, Biocon Limited Tel: +91 93236 48143 Email: aishwarya.sitharam@biocon.com Nikunj Mall, Biocon Biologics Limited Tel : +91 998 777 4078 Email: nikunj.mall@biocon.com 31 B I O C O N L I M I T E D 31